JP2021519060A - インビトロ培養及び移植のための組織構築物の生理学的3dバイオプリンティングのためのバイオガム及び植物性ガムハイドロゲルバイオインク - Google Patents
インビトロ培養及び移植のための組織構築物の生理学的3dバイオプリンティングのためのバイオガム及び植物性ガムハイドロゲルバイオインク Download PDFInfo
- Publication number
- JP2021519060A JP2021519060A JP2020549630A JP2020549630A JP2021519060A JP 2021519060 A JP2021519060 A JP 2021519060A JP 2020549630 A JP2020549630 A JP 2020549630A JP 2020549630 A JP2020549630 A JP 2020549630A JP 2021519060 A JP2021519060 A JP 2021519060A
- Authority
- JP
- Japan
- Prior art keywords
- tissue
- gum
- disease
- bioprinted
- organ
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 17
- 238000000338 in vitro Methods 0.000 title claims description 14
- 229920001938 Vegetable gum Polymers 0.000 title claims description 12
- 238000002054 transplantation Methods 0.000 title claims description 11
- 210000001519 tissue Anatomy 0.000 claims abstract description 172
- 210000004027 cell Anatomy 0.000 claims abstract description 85
- 239000000203 mixture Substances 0.000 claims abstract description 75
- 239000012620 biological material Substances 0.000 claims abstract description 28
- 230000000813 microbial effect Effects 0.000 claims abstract description 21
- 239000003102 growth factor Substances 0.000 claims abstract description 12
- 230000004962 physiological condition Effects 0.000 claims abstract description 10
- 210000000056 organ Anatomy 0.000 claims description 51
- 238000000034 method Methods 0.000 claims description 49
- 241000196324 Embryophyta Species 0.000 claims description 38
- 229920002581 Glucomannan Polymers 0.000 claims description 31
- 229920000591 gum Polymers 0.000 claims description 31
- 229940046240 glucomannan Drugs 0.000 claims description 29
- 201000010099 disease Diseases 0.000 claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
- 244000005700 microbiome Species 0.000 claims description 21
- 230000007547 defect Effects 0.000 claims description 18
- 229920001285 xanthan gum Polymers 0.000 claims description 16
- 235000010493 xanthan gum Nutrition 0.000 claims description 15
- 239000000230 xanthan gum Substances 0.000 claims description 15
- 229940082509 xanthan gum Drugs 0.000 claims description 15
- 239000002562 thickening agent Substances 0.000 claims description 14
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 12
- 229920002148 Gellan gum Polymers 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 235000010418 carrageenan Nutrition 0.000 claims description 11
- 229920001525 carrageenan Polymers 0.000 claims description 11
- 239000000679 carrageenan Substances 0.000 claims description 11
- 229940113118 carrageenan Drugs 0.000 claims description 11
- 235000010492 gellan gum Nutrition 0.000 claims description 11
- 239000000216 gellan gum Substances 0.000 claims description 11
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 11
- 229920001661 Chitosan Polymers 0.000 claims description 10
- 210000000988 bone and bone Anatomy 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 239000001814 pectin Substances 0.000 claims description 10
- 229920001277 pectin Polymers 0.000 claims description 10
- 235000010987 pectin Nutrition 0.000 claims description 10
- 238000012360 testing method Methods 0.000 claims description 10
- 241000233866 Fungi Species 0.000 claims description 9
- 238000004132 cross linking Methods 0.000 claims description 9
- 230000008439 repair process Effects 0.000 claims description 9
- 229920000161 Locust bean gum Polymers 0.000 claims description 8
- 208000019693 Lung disease Diseases 0.000 claims description 8
- 229920002310 Welan gum Polymers 0.000 claims description 8
- 229920002678 cellulose Polymers 0.000 claims description 8
- 239000001913 cellulose Substances 0.000 claims description 8
- 210000005260 human cell Anatomy 0.000 claims description 8
- 235000010420 locust bean gum Nutrition 0.000 claims description 8
- 239000000711 locust bean gum Substances 0.000 claims description 8
- 241000416162 Astragalus gummifer Species 0.000 claims description 7
- 206010016654 Fibrosis Diseases 0.000 claims description 7
- 235000010443 alginic acid Nutrition 0.000 claims description 7
- 229920000615 alginic acid Polymers 0.000 claims description 7
- 239000000090 biomarker Substances 0.000 claims description 7
- 230000004761 fibrosis Effects 0.000 claims description 7
- -1 methacrylyl Chemical group 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 6
- 108010010803 Gelatin Proteins 0.000 claims description 6
- 229920002907 Guar gum Polymers 0.000 claims description 6
- 229920000084 Gum arabic Polymers 0.000 claims description 6
- 229920001046 Nanocellulose Polymers 0.000 claims description 6
- 235000010489 acacia gum Nutrition 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 239000008273 gelatin Substances 0.000 claims description 6
- 229920000159 gelatin Polymers 0.000 claims description 6
- 235000019322 gelatine Nutrition 0.000 claims description 6
- 235000011852 gelatine desserts Nutrition 0.000 claims description 6
- 235000010417 guar gum Nutrition 0.000 claims description 6
- 239000000665 guar gum Substances 0.000 claims description 6
- 229960002154 guar gum Drugs 0.000 claims description 6
- 210000003205 muscle Anatomy 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 5
- 102000008186 Collagen Human genes 0.000 claims description 5
- 108010035532 Collagen Proteins 0.000 claims description 5
- 206010039491 Sarcoma Diseases 0.000 claims description 5
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 5
- 239000000205 acacia gum Substances 0.000 claims description 5
- 208000029162 bladder disease Diseases 0.000 claims description 5
- 210000000845 cartilage Anatomy 0.000 claims description 5
- 229920001436 collagen Polymers 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 208000016097 disease of metabolism Diseases 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 238000009509 drug development Methods 0.000 claims description 5
- 238000007877 drug screening Methods 0.000 claims description 5
- 208000019622 heart disease Diseases 0.000 claims description 5
- 229920002674 hyaluronan Polymers 0.000 claims description 5
- 229960003160 hyaluronic acid Drugs 0.000 claims description 5
- 208000028774 intestinal disease Diseases 0.000 claims description 5
- 208000017169 kidney disease Diseases 0.000 claims description 5
- 208000019423 liver disease Diseases 0.000 claims description 5
- 208000030159 metabolic disease Diseases 0.000 claims description 5
- 208000017497 prostate disease Diseases 0.000 claims description 5
- 235000010491 tara gum Nutrition 0.000 claims description 5
- 239000000213 tara gum Substances 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 208000026533 urinary bladder disease Diseases 0.000 claims description 5
- 230000002792 vascular Effects 0.000 claims description 5
- 230000029663 wound healing Effects 0.000 claims description 5
- 229920000936 Agarose Polymers 0.000 claims description 4
- 102000016942 Elastin Human genes 0.000 claims description 4
- 108010014258 Elastin Proteins 0.000 claims description 4
- 206010016717 Fistula Diseases 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- 229920001615 Tragacanth Polymers 0.000 claims description 4
- 206010006007 bone sarcoma Diseases 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 229920002549 elastin Polymers 0.000 claims description 4
- 230000003890 fistula Effects 0.000 claims description 4
- 230000001575 pathological effect Effects 0.000 claims description 4
- 230000004242 retinal defects Effects 0.000 claims description 4
- 230000017423 tissue regeneration Effects 0.000 claims description 4
- 235000010487 tragacanth Nutrition 0.000 claims description 4
- 239000000196 tragacanth Substances 0.000 claims description 4
- 229940116362 tragacanth Drugs 0.000 claims description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N 2,3,4,5-tetrahydroxypentanal Chemical compound OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 3
- 102000009123 Fibrin Human genes 0.000 claims description 3
- 108010073385 Fibrin Proteins 0.000 claims description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 3
- 239000000783 alginic acid Substances 0.000 claims description 3
- 229960001126 alginic acid Drugs 0.000 claims description 3
- 150000004781 alginic acids Chemical class 0.000 claims description 3
- 239000000084 colloidal system Substances 0.000 claims description 3
- 238000012136 culture method Methods 0.000 claims description 3
- 230000018109 developmental process Effects 0.000 claims description 3
- 238000005538 encapsulation Methods 0.000 claims description 3
- 229950003499 fibrin Drugs 0.000 claims description 3
- 239000003349 gelling agent Substances 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 230000008719 thickening Effects 0.000 claims description 3
- 230000025366 tissue development Effects 0.000 claims description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 102000012422 Collagen Type I Human genes 0.000 claims description 2
- 108010022452 Collagen Type I Proteins 0.000 claims description 2
- 206010061818 Disease progression Diseases 0.000 claims description 2
- 108010049003 Fibrinogen Proteins 0.000 claims description 2
- 102000008946 Fibrinogen Human genes 0.000 claims description 2
- 108090000190 Thrombin Proteins 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 230000000975 bioactive effect Effects 0.000 claims description 2
- 239000003181 biological factor Substances 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 230000005750 disease progression Effects 0.000 claims description 2
- 229940012952 fibrinogen Drugs 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 229960004072 thrombin Drugs 0.000 claims description 2
- 238000013334 tissue model Methods 0.000 claims description 2
- 229920001222 biopolymer Polymers 0.000 claims 2
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 claims 1
- 125000003147 glycosyl group Chemical group 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 229920003087 methylethyl cellulose Polymers 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 abstract description 16
- 239000005017 polysaccharide Substances 0.000 abstract description 16
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 abstract description 6
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 abstract description 6
- 230000003833 cell viability Effects 0.000 abstract description 6
- 230000003915 cell function Effects 0.000 abstract description 5
- 210000002744 extracellular matrix Anatomy 0.000 abstract description 5
- 230000002538 fungal effect Effects 0.000 abstract description 4
- 238000010586 diagram Methods 0.000 abstract 1
- 150000004676 glycans Chemical class 0.000 abstract 1
- 150000004804 polysaccharides Chemical class 0.000 description 15
- 238000003860 storage Methods 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 9
- 238000007639 printing Methods 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 8
- 239000000499 gel Substances 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 5
- 108010022355 Fibroins Proteins 0.000 description 5
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 235000010413 sodium alginate Nutrition 0.000 description 5
- 239000000661 sodium alginate Substances 0.000 description 5
- 229940005550 sodium alginate Drugs 0.000 description 5
- 238000010146 3D printing Methods 0.000 description 4
- 241001289435 Astragalus brachycalyx Species 0.000 description 4
- 241000220223 Fragaria Species 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- JUYQFRXNMVWASF-UHFFFAOYSA-M lithium;phenyl-(2,4,6-trimethylbenzoyl)phosphinate Chemical compound [Li+].CC1=CC(C)=CC(C)=C1C(=O)P([O-])(=O)C1=CC=CC=C1 JUYQFRXNMVWASF-UHFFFAOYSA-M 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 230000003204 osmotic effect Effects 0.000 description 4
- 201000002528 pancreatic cancer Diseases 0.000 description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 3
- 241000220479 Acacia Species 0.000 description 3
- 244000215068 Acacia senegal Species 0.000 description 3
- 235000006491 Acacia senegal Nutrition 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 3
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 3
- PNNNRSAQSRJVSB-BXKVDMCESA-N aldehydo-L-rhamnose Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O PNNNRSAQSRJVSB-BXKVDMCESA-N 0.000 description 3
- 229940072056 alginate Drugs 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000000711 cancerogenic effect Effects 0.000 description 3
- 231100000315 carcinogenic Toxicity 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 229960003082 galactose Drugs 0.000 description 3
- 229930182830 galactose Natural products 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- AVPCPPOOQICIRJ-UHFFFAOYSA-L sodium glycerol 2-phosphate Chemical compound [Na+].[Na+].OCC(CO)OP([O-])([O-])=O AVPCPPOOQICIRJ-UHFFFAOYSA-L 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- 244000247812 Amorphophallus rivieri Species 0.000 description 2
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 2
- 241001061264 Astragalus Species 0.000 description 2
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 2
- 241000206575 Chondrus crispus Species 0.000 description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- 125000003436 D-mannopyranosyl group Chemical group [H]OC([H])([H])[C@@]1([H])OC([H])(*)[C@@]([H])(O[H])[C@@]([H])(O[H])[C@]1([H])O[H] 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 229920002971 Heparan sulfate Polymers 0.000 description 2
- 229920002752 Konjac Polymers 0.000 description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 101710204410 Scaffold protein Proteins 0.000 description 2
- 241000736131 Sphingomonas Species 0.000 description 2
- 241000569510 Spino Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 241001196572 Vachellia Species 0.000 description 2
- 241001469176 Xanthomonas arboricola pv. juglandis Species 0.000 description 2
- 241000520892 Xanthomonas axonopodis Species 0.000 description 2
- 241000589636 Xanthomonas campestris Species 0.000 description 2
- 241000194062 Xanthomonas phaseoli Species 0.000 description 2
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 2
- 235000006533 astragalus Nutrition 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 210000000013 bile duct Anatomy 0.000 description 2
- 210000003321 cartilage cell Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 230000001434 glomerular Effects 0.000 description 2
- 239000000174 gluconic acid Substances 0.000 description 2
- 235000012208 gluconic acid Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000021374 legumes Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229920003213 poly(N-isopropyl acrylamide) Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 2
- 239000008914 rhamnogalacturonan II Substances 0.000 description 2
- 238000001338 self-assembly Methods 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 235000019832 sodium triphosphate Nutrition 0.000 description 2
- 235000021012 strawberries Nutrition 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 238000010408 sweeping Methods 0.000 description 2
- 150000004044 tetrasaccharides Chemical group 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 1
- VNQXSTWCDUXYEZ-UHFFFAOYSA-N 1,7,7-trimethylbicyclo[2.2.1]heptane-2,3-dione Chemical compound C1CC2(C)C(=O)C(=O)C1C2(C)C VNQXSTWCDUXYEZ-UHFFFAOYSA-N 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- KWVGIHKZDCUPEU-UHFFFAOYSA-N 2,2-dimethoxy-2-phenylacetophenone Chemical compound C=1C=CC=CC=1C(OC)(OC)C(=O)C1=CC=CC=C1 KWVGIHKZDCUPEU-UHFFFAOYSA-N 0.000 description 1
- OXBLVCZKDOZZOJ-UHFFFAOYSA-N 2,3-Dihydrothiophene Chemical compound C1CC=CS1 OXBLVCZKDOZZOJ-UHFFFAOYSA-N 0.000 description 1
- NLGDWWCZQDIASO-UHFFFAOYSA-N 2-hydroxy-1-(7-oxabicyclo[4.1.0]hepta-1,3,5-trien-2-yl)-2-phenylethanone Chemical compound OC(C(=O)c1cccc2Oc12)c1ccccc1 NLGDWWCZQDIASO-UHFFFAOYSA-N 0.000 description 1
- XMLYCEVDHLAQEL-UHFFFAOYSA-N 2-hydroxy-2-methyl-1-phenylpropan-1-one Chemical compound CC(C)(O)C(=O)C1=CC=CC=C1 XMLYCEVDHLAQEL-UHFFFAOYSA-N 0.000 description 1
- VHSHLMUCYSAUQU-UHFFFAOYSA-N 2-hydroxypropyl methacrylate Chemical compound CC(O)COC(=O)C(C)=C VHSHLMUCYSAUQU-UHFFFAOYSA-N 0.000 description 1
- IBZYPBGPOGJMBF-UHFFFAOYSA-N 3,6 anhydrogalactose Natural products CCC=CCC1C(CC(=O)NC(C(C)CC)C(O)=O)CCC1=O IBZYPBGPOGJMBF-UHFFFAOYSA-N 0.000 description 1
- WZYRMLAWNVOIEX-BGPJRJDNSA-N 3,6-anhydro-D-galactose Chemical compound O=C[C@H](O)[C@H]1OC[C@@H](O)[C@@H]1O WZYRMLAWNVOIEX-BGPJRJDNSA-N 0.000 description 1
- UBLAMKHIFZBBSS-UHFFFAOYSA-N 3-Methylbutyl pentanoate Chemical compound CCCCC(=O)OCCC(C)C UBLAMKHIFZBBSS-UHFFFAOYSA-N 0.000 description 1
- DCQFFOLNJVGHLW-UHFFFAOYSA-N 4'-Me ether-Punctatin+ Natural products O1C(O)C(O)C2OCC1C2O DCQFFOLNJVGHLW-UHFFFAOYSA-N 0.000 description 1
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 1
- IICCLYANAQEHCI-UHFFFAOYSA-N 4,5,6,7-tetrachloro-3',6'-dihydroxy-2',4',5',7'-tetraiodospiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 IICCLYANAQEHCI-UHFFFAOYSA-N 0.000 description 1
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 235000006509 Acacia nilotica Nutrition 0.000 description 1
- 235000011438 Albizia odoratissima Nutrition 0.000 description 1
- 240000005482 Albizia procera Species 0.000 description 1
- 241000588986 Alcaligenes Species 0.000 description 1
- 241000588813 Alcaligenes faecalis Species 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 description 1
- 241000223678 Aureobasidium pullulans Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091016585 CD44 antigen Proteins 0.000 description 1
- NOLVNUOQUJETRB-NCZNAIGRSA-N C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O Chemical group C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O NOLVNUOQUJETRB-NCZNAIGRSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 241000407877 Combretum Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 239000001879 Curdlan Substances 0.000 description 1
- 229920002558 Curdlan Polymers 0.000 description 1
- PJWWRFATQTVXHA-UHFFFAOYSA-N Cyclohexylaminopropanesulfonic acid Chemical compound OS(=O)(=O)CCCNC1CCCCC1 PJWWRFATQTVXHA-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-DTEWXJGMSA-N D-Galacturonic acid Natural products O[C@@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-DTEWXJGMSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241000940372 Eucheuma denticulatum Species 0.000 description 1
- 241000483002 Euproctis similis Species 0.000 description 1
- 229920002444 Exopolysaccharide Polymers 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 235000017367 Guainella Nutrition 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 206010072877 Intestinal fibrosis Diseases 0.000 description 1
- 241001519524 Kappaphycus alvarezii Species 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- WQZGKKKJIJFFOK-JFNONXLTSA-N L-mannopyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O WQZGKKKJIJFFOK-JFNONXLTSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical group C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000007990 PIPES buffer Substances 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- 241001308622 Senegalia <Bacteria> Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108090000054 Syndecan-2 Proteins 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 241000589634 Xanthomonas Species 0.000 description 1
- 241000567083 Xanthomonas arboricola Species 0.000 description 1
- 241000589655 Xanthomonas citri Species 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- 108010054251 arabinogalactan proteins Proteins 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000001052 bipolar neuron Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 229930006711 bornane-2,3-dione Natural products 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000022159 cartilage development Effects 0.000 description 1
- 239000012952 cationic photoinitiator Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000002648 chondrogenic effect Effects 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- WZYRMLAWNVOIEX-UHFFFAOYSA-N cinnamtannin B-2 Natural products O=CC(O)C1OCC(O)C1O WZYRMLAWNVOIEX-UHFFFAOYSA-N 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 210000002777 columnar cell Anatomy 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 235000019316 curdlan Nutrition 0.000 description 1
- 229940078035 curdlan Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 210000005232 distal tubule cell Anatomy 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000000613 ear canal Anatomy 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 210000003890 endocrine cell Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- UKZQEOHHLOYJLY-UHFFFAOYSA-M ethyl eosin Chemical compound [K+].CCOC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 UKZQEOHHLOYJLY-UHFFFAOYSA-M 0.000 description 1
- 210000002907 exocrine cell Anatomy 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012949 free radical photoinitiator Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 108700004892 gelatin methacryloyl Proteins 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000000003 hoof Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 235000010485 konjac Nutrition 0.000 description 1
- 210000004561 lacrimal apparatus Anatomy 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 150000002704 mannoses Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000000716 merkel cell Anatomy 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 210000003078 multipolar neuron Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- QYZFTMMPKCOTAN-UHFFFAOYSA-N n-[2-(2-hydroxyethylamino)ethyl]-2-[[1-[2-(2-hydroxyethylamino)ethylamino]-2-methyl-1-oxopropan-2-yl]diazenyl]-2-methylpropanamide Chemical compound OCCNCCNC(=O)C(C)(C)N=NC(C)(C)C(=O)NCCNCCO QYZFTMMPKCOTAN-UHFFFAOYSA-N 0.000 description 1
- LKQUCICFTHBFAL-UHFFFAOYSA-N n-benzylbenzamide Chemical compound C=1C=CC=CC=1C(=O)NCC1=CC=CC=C1 LKQUCICFTHBFAL-UHFFFAOYSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 229940080818 propionamide Drugs 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 210000002763 pyramidal cell Anatomy 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229930187593 rose bengal Natural products 0.000 description 1
- 229940081623 rose bengal Drugs 0.000 description 1
- STRXNPAVPKGJQR-UHFFFAOYSA-N rose bengal A Natural products O1C(=O)C(C(=CC=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 STRXNPAVPKGJQR-UHFFFAOYSA-N 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 210000002325 somatostatin-secreting cell Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004500 stellate cell Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000023895 stem cell maintenance Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000012815 thermoplastic material Substances 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 150000004043 trisaccharides Chemical group 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 210000003242 unipolar neuron Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- FYGDTMLNYKFZSV-BYLHFPJWSA-N β-1,4-galactotrioside Chemical group O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-BYLHFPJWSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3637—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the origin of the biological material other than human or animal, e.g. plant extracts, algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/717—Celluloses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/46—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y10/00—Processes of additive manufacturing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y50/00—Data acquisition or data processing for additive manufacturing
- B33Y50/02—Data acquisition or data processing for additive manufacturing for controlling or regulating additive manufacturing processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y80/00—Products made by additive manufacturing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
- C12M25/14—Scaffolds; Matrices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y70/00—Materials specially adapted for additive manufacturing
- B33Y70/10—Composites of different types of material, e.g. mixtures of ceramics and polymers or mixtures of metals and biomaterials
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0068—General culture methods using substrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Materials Engineering (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Composite Materials (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Manufacturing & Machinery (AREA)
- Dispersion Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Sustainable Development (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
Abstract
Description
[0001] 本出願は、2018年10月25日に出願された米国仮特許出願第62/750,390号及び62/750,417号の開示に依拠し、優先権及び出願日の利益を主張するものであり、それぞれはその全体が参照により本明細書に組み込まれる。
発明の分野
[0002] 本発明は、3Dバイオプリンティング及び機能的組織工学の新たな分野に関する。より具体的には、本発明の実施形態は、インビトロ培養、移植、組織の発達、並びに薬物スクリーニング及び開発におけるその後の使用のための哺乳動物及びヒト組織構築物のバイオプリンティングで使用可能なバイオインクを構成するために、生体適合性生体材料と組み合わせてバイオガム及び/又は植物性ガムを含む、組成物に関する。
[0003] 3次元(3D)プリンティングプロセスでは、コンピューター支援設計であるCADファイルを使用して、プリンター装置によって層ごとにオブジェクトが製作される。3Dプリンティングは、患者固有の足場を製作するために、多くの科学者たちによって、組織工学で既に成功裏に使用されている。熱可塑性ポリマーで作製された足場は、3Dプリンターを使用して押出成形されている。熱可塑性材料を使用した3Dプリンティングの欠点は、多孔性構造への細胞遊走が制限されているため、細胞播種が困難なことである。3Dバイオプリンティングは、室温又は体温の液体を使用して動作するため、生細胞を処理できる可能性がある。3Dバイオプリンティングの導入は、組織工学及び再生医療の分野に革命をもたらすと期待されており、これにより、好ましくは患者自身の細胞を使用して、生体組織及び器官の再構築が可能となり得る。3Dバイオプリンターは、液体を分注しながら10μmの解像度でC、U、Z方向に移動できるロボットアームである。3Dバイオプリンターは、複数の細胞タイプを配置できるため、複雑な器官の構造を再構築できる。3D組織の階層アセンブリの必要性は、新技術が高度な組織の製作に不可欠であることを考えると、ますます重要になっている。3D細胞プリンティングは、天然組織の微小環境を再現する強力な技術として登場し、事前定義された位置に複数の細胞を正確に沈着させることができる。これらの技術の進歩と並行して、細胞活動を支持する適切な微小環境を提供することのできる適切なバイオインクについての探索が脚光を浴びている。バイオインクは、多くの場合、細胞生存能力及び生物学的活性を維持しながら、プリント適性を付与するために増粘剤と混合された低粘度又は温度感受性生体材料を含む。
[0004] 実施形態によれば、微生物由来のガム(例えば、キサンタンガム)又は植物由来(例えば、植物性)などのバイオガムは、様々な生体材料と組み合わせて増粘剤として利用され、プリンティングノズル及びパラメーターの範囲に互換性のあるプリント可能なバイオインクを製作する。本発明の実施形態は、ヒト組織及び足場の3Dバイオプリンティングにおける使用のための、細胞を伴い又は伴わない、1つの生体材料ベースのハイドロゲル(哺乳動物、植物ベース、又は微生物由来)又は合成ハイドロゲル、及び増粘剤(例えば、キサンタンガム、ジェランガム、デュータンガム、ウェランガム、プルランガム、アカシアガム、タラガム、グルコマンナン、ペクチン、ローカストビーンガム、グアーガム、カラギーナン及びトラガカント)として作用する、1つの微生物、真菌、若しくは植物ベースの、又はそれにより産生された、生体適合性多糖類、の2つのポリマーの組み合わせが、優れたプリント適正並びに改善された細胞機能、生存能力及び生着をもたらすという発見に依存する。
[0118] 添付の図面は、本発明の実施形態の一定の態様を示しており、本発明を限定するために使用されるべきではない。書面による説明とともに、図面は本発明の一定の原理を説明するのに役立つ。
[0134] 用語の定義及び請求の特徴
ヒト組織及び足場の3Dバイオプリンティングにおける使用のための、細胞を伴い又は伴わず、ハイドロゲル及び微生物産生、真菌産生、又は植物産生の多糖類などの生体材料(哺乳動物、植物ベース、合成由来、又は微生物由来)を含む、バイオインク組成物が記載される。バイオインク組成物は、優れたプリント適性及び改善された細胞機能、生存能力並びに生着性を有する。さらに、バイオインク組成物は、補助タンパク質、及び細胞外マトリックス成分、ラミニン、超親和性成長因子及びモルフォゲンを含む成長因子などの他の分子の添加により補完することができる。バイオインク組成物は、細胞適合性である3Dバイオプリンティングパラメーター(例えば、温度、プリント圧力、ノズルサイズ、バイオインクゲル化プロセス)に関する生理学的条件下で使用することができる。哺乳動物、植物、微生物又は合成的に誘導されたハイドロゲルとのバイオガムベース生体材料の組み合わせは、バイオガムを含有しないバイオインクでプリントされた組織と比較して、プリント適正、細胞機能及び生存能力の改善を示した。
Claims (42)
- ヒト又は動物組織の3Dバイオプリンティング及び培養における使用のためのバイオインク組成物であって、
(i)1つ以上の微生物、真菌、若しくは植物ベースの、又はそれにより産生されたバイオガム、及び
(ii)哺乳動物、植物、微生物、又は合成的に誘導されたハイドロゲルに由来する、1つ以上の生体材料
を含む、バイオインク組成物。 - 生細胞をさらに含む、請求項1に記載の組成物。
- 1つ以上の前記バイオガムと1つ以上の前記生体材料との比率が、5:95から95:5の範囲である、請求項1又は2に記載の組成物。
- 1つ以上の前記生体材料が、前記組成物のレオロジー特性に架橋及び/又は寄与することができる、少なくとも1つの親水コロイド又は増粘及びゲル化剤を含む、請求項1又は2に記載の組成物。
- 1つ以上の前記バイオガムが、微生物ガム又は植物性ガムを含む、請求項1又は2に記載の組成物。
- 前記組成物が、バイオインクのレオロジー特性に架橋及び/又は寄与することができる、1つ以上の追加のバイオポリマーを含む、請求項1又は2に記載の組成物。
- 前記1つ以上の追加のバイオポリマーが、1つ以上のアルギン酸塩、ヒアルロン酸及びその誘導体、アガロース及びその誘導体、キトサン、フィブリン、ジェランガム、シルク及びその誘導体、ナノフィブリル化セルロース、ミクロフィブリル化セルロース、結晶ナノセルロース、細菌ナノセルロース、カラギーナン、エラスチン、コラーゲン及びその誘導体、ゼラチン及びその誘導体、又はそれらの任意の組み合わせを含む、請求項6に記載の組成物。
- 前記細胞が、10万/mlから1億5,000万/mlの範囲の濃度を有する、請求項2に記載の組成物。
- 前記細胞が、ヒト又はブタ細胞である、請求項2に記載の組成物。
- 前記組成物が、生理学的条件でヒト又は動物組織の3Dバイオプリンティング及び/又は培養において使用することができる、請求項1又は2に記載の組成物。
- 前記生理学的条件が、
a.5から8の範囲の組成物のpH値;及び/又は
b.275から300mOsm/kgの範囲の組成物の浸透圧、
を含む、請求項10に記載の組成物。 - 1つ以上の微生物、真菌、若しくは植物ベースの、又はそれにより産生された、バイオガム、及び哺乳動物、植物、微生物、又は合成的に誘導されたハイドロゲルに由来する、1つ以上の生体材料を含む組成物を、前記1つ以上のバイオガム及び前記1つ以上の生体材料を、ヒト又は哺乳動物細胞と組み合わせる態様で、バイオプリンティングすることを含む、ヒト又は哺乳動物組織の3Dバイオプリンティング方法。
- 1つ以上の微生物、真菌、若しくは植物ベースの、又はそれにより産生された、バイオガム、及び哺乳動物、植物、微生物、又は合成的に誘導されたハイドロゲルに由来する、1つ以上の生体材料を含む組成物を、少なくとも1つの足場を形成する方法で、バイオプリンティングすることを含む、少なくとも1つの足場の3Dバイオプリンティング方法。
- a.前記3Dバイオプリンティング中の温度が4℃から40℃の範囲である;及び/又は
b.前記3Dバイオプリンティング中のプリント圧力が1から200kPaの範囲である、
請求項12又は13に記載の方法。 - 1つ以上の微生物、真菌、若しくは植物ベースの、又はそれにより産生された、バイオガム、及び哺乳動物、植物、微生物、又は合成的に誘導されたハイドロゲルに由来する、1つ以上の生体材料を含む組成物を含むか、又は前記組成物をバイオプリンティングすることによって調製される、バイオプリントされた組織又は器官であって、1つ以上の前記微生物、真菌、若しくは植物ベースの、又はそれにより産生されたバイオガム、及び1つ以上の前記生体材料を、ヒト又は哺乳動物細胞と組み合わせる態様でバイオプリントされる、バイオプリントされた組織又は器官。
- 肝臓疾患、代謝性疾患、糖尿病、心臓病、腎臓疾患、肺疾患、皮膚欠損、筋肉欠損、骨欠損、骨及び軟部組織肉腫、肺疾患、血管修復、腸疾患、瘻孔、軟骨欠損、網膜欠損、膀胱疾患、前立腺疾患、組織線維症、又は癌の治療用途における使用のための、請求項15に記載のバイオプリントされた組織又は器官。
- 請求項15又は16に記載のバイオプリントされた組織又は器官を使用することを含む、肝臓疾患、代謝性疾患、糖尿病、心臓病、腎臓疾患、肺疾患、皮膚欠損、筋肉欠損、骨欠損、骨及び軟部組織肉腫、肺疾患、血管修復、腸疾患、瘻孔、軟骨欠損、網膜欠損、膀胱疾患、前立腺疾患、組織線維症、又は癌の処置方法。
- 生理学的又は病理学的条件下で前記バイオプリントされた組織又は器官を培養することを含む、請求項15又は16に記載のバイオプリントされた組織又は器官を培養する方法。
- 少なくとも2つのタイプの細胞が、1:1、1:5、1:10、1:25、1:50、1:100、1:150、及びその間の任意の範囲から選択される異なる比率で共培養されるか、又は、培養中の細胞タイプが2つを超える場合、前記比率が、1:1:1、1:1:5、1:1:10、1:1:50、1:1:100、及びその間の任意の範囲から選択される、請求項18に記載の方法。
- 前記バイオプリントされた組織又は器官は、インビトロ培養、疾患モデリング、薬物スクリーニング、バイオマーカー発見、薬物開発のための組織モデル、物質試験及び生物活性化合物効力試験を含む1つ以上の適用が可能である、請求項18に記載の方法。
- 請求項18に記載の培養方法により調製されたインビトロ培養物。
- 組織の発達、疾患の進行、薬物スクリーニング及び開発、並びにバイオマーカーのための、請求項21に記載のインビトロ培養物の使用。
- 請求項12又は13に記載の3Dバイオプリンティング方法によって調製された、バイオプリントされた組織又は足場。
- 成長因子をさらに含む、請求項23に記載のバイオプリントされた組織又は足場。
- 請求項23に記載のバイオプリントされた組織又は足場を病変組織又は器官に移植することを含む、組織修復を促進する方法。
- 請求項23に記載のバイオプリントされた組織又は足場を病変組織又は器官に移植することを含む、移植方法。
- 請求項23に記載のバイオプリントされた組織又は足場を創傷部に組織パッチとして移植することを含む、組織又は器官を修復する方法。
- 請求項23に記載のバイオプリントされた組織又は足場を、組織又は器官に注入、移植、カプセル化又は体外適用することを含む、前記組織又は器官の疾患を処置する方法。
- a.請求項23に記載のバイオプリントされた組織又は足場のサンプルを個体から提供するステップ;及び
b.前記サンプル中の1つ以上の足場又は組織のタンパク質の存在及び量を決定するステップ
を含み、
前記サンプル中の前記1つ以上の足場又は組織のタンパク質の存在及び量が、前記個体の前記組織又は器官における疾患の存在を示し、且つ処置への応答を反映し得る、ヒト個体の疾患を診断するための方法。 - a.請求項23に記載のバイオプリントされた組織又は足場を提供するステップ;及び
b.前記バイオプリントされた組織又は足場に対する、化合物、薬物、生物学的因子、機器又は治療的介入の効果を決定するステップ
を含む、疾患モデリングのための方法。 - a.病変組織又は器官への移植;
b.前記バイオプリントされた組織又は足場が、皮下又は網内に、又は組織パッチとして直接的に前記病変組織又は器官に異所的に移植される、ヒト又は動物の体への移植;
c.前記バイオプリントされた組織又は足場が、創傷治癒を改善するために組織パッチとして移植される、組織又は器官の修復;及び/又は
d.前記バイオプリントされた組織又は脱細胞化されたバイオプリントされた組織が、注射、移植、カプセル化、又は体外適用などにより、組織又は器官に適用される、前記組織又は器官の疾患の処置、
における使用のための、請求項23に記載のバイオプリントされた組織又は足場。 - 前記少なくとも1つの親水コロイド又は増粘及びゲル化剤が、I型コラーゲン、コラーゲン及びその誘導体、ゼラチンメタクリロイル、ゼラチン及びその誘導体、フィブリノーゲン、トロンビン、エラスチン、アルギン酸、アガロース及びその誘導体、ヒアルロン酸などのグリコサミノグリカン及びその誘導体、キトサン、低及び高メトキシペクチン、ジェランガム、デュータンガム、グルコマンナンガム、カラギーナン、ナノフィブリル化セルロース、ミクロフィブリル化セルロース、結晶性ナノセルロース、カルボキシメチルセルロース、メチル及びヒドロキシプロピルメチルセルロース、バクテリアナノセルロース、及びこれらの任意の組み合わせを含む、請求項4に記載の組成物。
- 前記微生物ガムが、0.5から10%(w/v)、又は20%w/vまでの範囲(5から15%w/v、又は約10%w/vなど)の濃度を有する、請求項5に記載の組成物。
- 前記植物性ガムが、0.5から50%(w/v)(0.6から1.2%w/v、又は約0.9%w/vなど(1%w/v以下など))の範囲の濃度を有する、請求項5に記載の組成物。
- 前記移植が、異所的に、皮下、網内、又は組織パッチとして直接的(前記病変組織又は器官内など)に配置される、請求項26に記載の方法。
- 1つ以上の前記バイオガムが、キサンタンガム、ジェランガム、デュータンガム、ウェランガム、又はプルランガム、又はそれらの組み合わせを含む微生物ガムである、請求項1に記載の組成物。
- 1つ以上の前記バイオガムが、アカシアガム、タラガム、グルコマンナン、ペクチン、ローカストビーンガム、グアーガム、カラギーナン、或いはトラガカント、又はそれらの組み合わせを含む植物性ガムである、請求項1に記載の組成物。
- 請求項1に記載の組成物と、カートリッジ、バイアル、又はシリンジとを含む、キット。
- 前記組成物が、前記カートリッジ、バイアル、又はシリンジに含有される、請求項38に記載のキット。
- 前記組成物が乾燥形態である、請求項39に記載のキット。
- 緩衝液又は溶媒をさらに含む、請求項38に記載のキット。
- 前記緩衝液又は溶媒が、前記カートリッジ、バイアル、又はシリンジに含有される、請求項41に記載のキット。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022035620A JP2022078243A (ja) | 2018-10-25 | 2022-03-08 | インビトロ培養及び移植のための組織構築物の生理学的3dバイオプリンティングのためのバイオガム及び植物性ガムハイドロゲルバイオインク |
JP2023064856A JP2023090746A (ja) | 2018-10-25 | 2023-04-12 | インビトロ培養及び移植のための組織構築物の生理学的3dバイオプリンティングのためのバイオガム及び植物性ガムハイドロゲルバイオインク |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862750390P | 2018-10-25 | 2018-10-25 | |
US201862750417P | 2018-10-25 | 2018-10-25 | |
US62/750,417 | 2018-10-25 | ||
US62/750,390 | 2018-10-25 | ||
PCT/US2019/058025 WO2020086941A1 (en) | 2018-10-25 | 2019-10-25 | Biogum and botanical gum hydrogel bioinks for the physiological 3d bioprinting of tissue constructs for in vitro culture and transplantation |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022035620A Division JP2022078243A (ja) | 2018-10-25 | 2022-03-08 | インビトロ培養及び移植のための組織構築物の生理学的3dバイオプリンティングのためのバイオガム及び植物性ガムハイドロゲルバイオインク |
JP2023064856A Division JP2023090746A (ja) | 2018-10-25 | 2023-04-12 | インビトロ培養及び移植のための組織構築物の生理学的3dバイオプリンティングのためのバイオガム及び植物性ガムハイドロゲルバイオインク |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021519060A true JP2021519060A (ja) | 2021-08-10 |
JP7312761B2 JP7312761B2 (ja) | 2023-07-21 |
Family
ID=70331736
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020549630A Active JP7312761B2 (ja) | 2018-10-25 | 2019-10-25 | インビトロ培養及び移植のための組織構築物の生理学的3dバイオプリンティングのためのバイオガム及び植物性ガムハイドロゲルバイオインク |
JP2022035620A Pending JP2022078243A (ja) | 2018-10-25 | 2022-03-08 | インビトロ培養及び移植のための組織構築物の生理学的3dバイオプリンティングのためのバイオガム及び植物性ガムハイドロゲルバイオインク |
JP2023064856A Pending JP2023090746A (ja) | 2018-10-25 | 2023-04-12 | インビトロ培養及び移植のための組織構築物の生理学的3dバイオプリンティングのためのバイオガム及び植物性ガムハイドロゲルバイオインク |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022035620A Pending JP2022078243A (ja) | 2018-10-25 | 2022-03-08 | インビトロ培養及び移植のための組織構築物の生理学的3dバイオプリンティングのためのバイオガム及び植物性ガムハイドロゲルバイオインク |
JP2023064856A Pending JP2023090746A (ja) | 2018-10-25 | 2023-04-12 | インビトロ培養及び移植のための組織構築物の生理学的3dバイオプリンティングのためのバイオガム及び植物性ガムハイドロゲルバイオインク |
Country Status (5)
Country | Link |
---|---|
US (1) | US20210001009A1 (ja) |
EP (1) | EP3799571A4 (ja) |
JP (3) | JP7312761B2 (ja) |
KR (2) | KR20220077156A (ja) |
WO (1) | WO2020086941A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024029629A1 (ja) * | 2022-08-04 | 2024-02-08 | 三栄源エフ・エフ・アイ株式会社 | 細胞培養用の多孔質足場及びその製造方法 |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11931966B2 (en) | 2018-01-26 | 2024-03-19 | Cellink Bioprinting Ab | Systems and methods for optical assessments of bioink printability |
WO2020077118A1 (en) | 2018-10-10 | 2020-04-16 | Cellink Ab | Double network bioinks |
US11826951B2 (en) | 2019-09-06 | 2023-11-28 | Cellink Ab | Temperature-controlled multi-material overprinting |
WO2021256995A1 (en) * | 2020-06-15 | 2021-12-23 | National University Of Singapore | A bioink |
KR102378122B1 (ko) * | 2020-08-12 | 2022-03-25 | 경북대학교 산학협력단 | 마이크로피브릴화 셀룰로오스 및 구아검을 포함하는 3d 바이오 프린팅용 바이오 잉크 및 3d 프린팅 방법 |
KR102566751B1 (ko) * | 2020-12-31 | 2023-08-18 | 경북대학교 산학협력단 | 마이크로피브릴화 셀룰로오스 및 로커스트콩검을 포함하는 3d 바이오 프린팅용 바이오 잉크 및 3d 프린팅 방법 |
CN112826635A (zh) * | 2021-01-26 | 2021-05-25 | 华中科技大学同济医学院附属协和医院 | 一种促进血管化乳房支架的制作方法 |
WO2022177496A1 (en) | 2021-02-17 | 2022-08-25 | Bico Group Ab | Bioprinting workflow systems and methods |
IT202100004412A1 (it) * | 2021-02-25 | 2022-08-25 | Univ Degli Studi Di Pavia | Bioinchiostri a fibroina di seta e relativi usi per biostampa 3d |
CN113244455B (zh) * | 2021-05-17 | 2022-08-05 | 广西医科大学 | 一种3d打印亚麻籽水凝胶支架及制备方法和应用 |
CN113215101B (zh) * | 2021-05-31 | 2022-08-12 | 清华大学 | 一种构建具有异质功能纤维和血管通道的纤维束/组织结构的方法 |
WO2023048674A1 (en) * | 2021-09-22 | 2023-03-30 | İzmi̇r Yüksek Teknoloji̇ Ensti̇tüsü | Development of glucuronoxylan-based bioink |
WO2023147518A1 (en) * | 2022-01-27 | 2023-08-03 | Board Of Trustees Of The University Of Arkansas | System and method for three-dimensional food printing |
CN116572524A (zh) * | 2023-05-17 | 2023-08-11 | 宁波大学 | 卡拉胶在生物3d打印中的应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010533855A (ja) * | 2007-07-19 | 2010-10-28 | ビオメリュー | 結腸直腸癌のインビトロ診断のためのアポリポタンパク質aii・アッセイ方法 |
WO2017210663A1 (en) * | 2016-06-03 | 2017-12-07 | Paul Gatenholm | Preparation and applications of rgd conjugated polysaccharide bioinks with or without fibrin for 3d bioprinting of human skin with novel printing head for use as model for testing cosmetics and for transplantation |
US20170368225A1 (en) * | 2014-12-18 | 2017-12-28 | Cellink Ab | Cellulose nanofibrillar bioink for 3d bioprinting for cell culturing, tissue engineering and regenerative medicine applications |
JP2018501845A (ja) * | 2014-12-11 | 2018-01-25 | イーティーエッチ チューリッヒ | 軟骨修復のための移植片足場及びその製造方法 |
WO2018187380A1 (en) * | 2017-04-03 | 2018-10-11 | Greene Nguyen Deborah Lynn | Use of engineered liver tissue constructs for modeling liver disorders |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180273904A1 (en) * | 2015-10-02 | 2018-09-27 | Wake Forest University Health Sciences | Spontaneously beating cardiac organoid constructs and integrated body-on-chip apparatus containing the same |
-
2019
- 2019-10-25 WO PCT/US2019/058025 patent/WO2020086941A1/en unknown
- 2019-10-25 KR KR1020227017436A patent/KR20220077156A/ko not_active Application Discontinuation
- 2019-10-25 US US16/979,452 patent/US20210001009A1/en active Pending
- 2019-10-25 JP JP2020549630A patent/JP7312761B2/ja active Active
- 2019-10-25 EP EP19874873.3A patent/EP3799571A4/en active Pending
- 2019-10-25 KR KR1020207031999A patent/KR20210047271A/ko not_active Application Discontinuation
-
2022
- 2022-03-08 JP JP2022035620A patent/JP2022078243A/ja active Pending
-
2023
- 2023-04-12 JP JP2023064856A patent/JP2023090746A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010533855A (ja) * | 2007-07-19 | 2010-10-28 | ビオメリュー | 結腸直腸癌のインビトロ診断のためのアポリポタンパク質aii・アッセイ方法 |
JP2018501845A (ja) * | 2014-12-11 | 2018-01-25 | イーティーエッチ チューリッヒ | 軟骨修復のための移植片足場及びその製造方法 |
US20170368225A1 (en) * | 2014-12-18 | 2017-12-28 | Cellink Ab | Cellulose nanofibrillar bioink for 3d bioprinting for cell culturing, tissue engineering and regenerative medicine applications |
WO2017210663A1 (en) * | 2016-06-03 | 2017-12-07 | Paul Gatenholm | Preparation and applications of rgd conjugated polysaccharide bioinks with or without fibrin for 3d bioprinting of human skin with novel printing head for use as model for testing cosmetics and for transplantation |
WO2018187380A1 (en) * | 2017-04-03 | 2018-10-11 | Greene Nguyen Deborah Lynn | Use of engineered liver tissue constructs for modeling liver disorders |
Non-Patent Citations (2)
Title |
---|
PANWAR A ET AL.: "Current status of bioinks for micro-extrusion-based 3D bioprinting.", MOLECULES, vol. 21, no. 6, JPN6021007025, 25 May 2016 (2016-05-25), pages 685, XP055447352, ISSN: 0004532033, DOI: 10.3390/molecules21060685 * |
ZHAO YU ET AL.: "Three-demensional printing of Hela cells for cervical tumor model in vitro", BIOFABRICATION, vol. 6, no. 3, JPN6022014861, 11 April 2014 (2014-04-11), pages 035001, ISSN: 0004752082 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024029629A1 (ja) * | 2022-08-04 | 2024-02-08 | 三栄源エフ・エフ・アイ株式会社 | 細胞培養用の多孔質足場及びその製造方法 |
Also Published As
Publication number | Publication date |
---|---|
KR20220077156A (ko) | 2022-06-08 |
US20210001009A1 (en) | 2021-01-07 |
EP3799571A4 (en) | 2022-03-09 |
JP2023090746A (ja) | 2023-06-29 |
EP3799571A1 (en) | 2021-04-07 |
WO2020086941A1 (en) | 2020-04-30 |
KR20210047271A (ko) | 2021-04-29 |
JP2022078243A (ja) | 2022-05-24 |
JP7312761B2 (ja) | 2023-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7312761B2 (ja) | インビトロ培養及び移植のための組織構築物の生理学的3dバイオプリンティングのためのバイオガム及び植物性ガムハイドロゲルバイオインク | |
Reakasame et al. | Oxidized alginate-based hydrogels for tissue engineering applications: a review | |
Christensen | Alginates as biomaterials in tissue engineering | |
Radhakrishnan et al. | Injectable and 3D bioprinted polysaccharide hydrogels: from cartilage to osteochondral tissue engineering | |
JP6762936B2 (ja) | 軟骨修復のための移植片足場及びその製造方法 | |
JP6821583B2 (ja) | キトサン及び軟骨細胞を含む軟骨修復のための軟骨ゲル | |
Burdick et al. | Hyaluronic acid hydrogels for biomedical applications | |
Park et al. | Injectable chitosan hyaluronic acid hydrogels for cartilage tissue engineering | |
Oliveira et al. | Polysaccharide‐based materials for cartilage tissue engineering applications | |
JP6757329B2 (ja) | 自己組み込み型ヒドロゲル及びその製造方法 | |
Iwasaki et al. | Feasibility of polysaccharide hybrid materials for scaffolds in cartilage tissue engineering: evaluation of chondrocyte adhesion to polyion complex fibers prepared from alginate and chitosan | |
Jose et al. | Natural polymers based hydrogels for cell culture applications | |
US20220025309A1 (en) | Microfluidic Device Facilitating Perfusion of Mammalian and Human Tissue Constructs | |
WO2014133027A1 (ja) | ハイドロゲル | |
Zhang et al. | Application of hydrogels in heart valve tissue engineering | |
JP2004535836A (ja) | 架橋ヒアルロン酸−ラミニンゲル並びに細胞培養及び医療用移植組織におけるその使用 | |
Gelinsky | Biopolymer hydrogel bioinks | |
JP7210095B2 (ja) | 化学架橋アルギン酸を用いた移植用デバイス | |
CN109069692A (zh) | 椎间盘治疗用组合物 | |
Mahboubian et al. | Temperature-responsive methylcellulose–hyaluronic hydrogel as a 3D cell culture matrix | |
Szustak et al. | Nanocellulose-based scaffolds for chondrogenic differentiation and expansion | |
Shanto et al. | Physico-biological evaluation of 3D printed dECM/TOCN/alginate hydrogel based scaffolds for cartilage tissue regeneration | |
Pattanashetti et al. | Polysaccharides as novel materials for tissue engineering applications | |
JP4017958B2 (ja) | 細胞培養担体 | |
Cassano et al. | Polysaccharides and proteins-based hydrogels for tissue engineering applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201127 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201127 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20201127 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20210426 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210621 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210921 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211119 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211209 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220308 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220418 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220715 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220818 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221104 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20221212 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230412 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20230412 |
|
C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20230421 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20230517 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230614 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230710 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7312761 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |